Storm Therapeutics

Name

Storm Therapeutics

Legal name

STORM Therapeutics Limited

Website

https://stormtherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• RNA epigenetics drugs
• METTL3 inhibitor
• Small molecule oncology
• Cancer therapeutics
• RNA methyltransferase inhibitors

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Milestone Payments: Pre-commercial biotech generating revenue through partnering deals. Received $17M upfront from Exelixis for ADAR1 collaboration. Eligible for development, regulatory and commercialization milestones plus tiered royalties on net sales.
2. Clinical Development Partnerships: Co-development arrangements where partners provide drug supply and/or funding. Coherus provides LOQTORZI for Phase 1b/2 combination study while STORM sponsors the trial.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

STORM Therapeutics develops first-in-class small-molecule drugs that inhibit RNA-modifying enzymes (RMEs) to treat cancer and other diseases. Its lead asset, STC-15, is an oral METTL3 RNA methyltransferase inhibitor currently in Phase 2 clinical development for selected sarcomas and in Phase 1b/2 combination studies with checkpoint inhibitors. The company also advances preclinical programs against METTL1 and ADAR1 through its proprietary RNA Epigenetic Platform combining mass spectrometry screening with the NASE computational algorithm.

Product overview

Storm Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications. The company's proprietary platform enables discovery of first-in-class small molecule drugs targeting RNA modifying enzymes (RMEs). Lead product STC-15 is the first RNA-modifying enzyme inhibitor to enter human clinical trials - an oral METTL3 inhibitor currently in Phase 2 for sarcoma with combination studies ongoing. The pipeline also includes METTL1 inhibitors (preclinical) and an ADAR1 inhibitor program (licensed to Exelixis).

Differentiator

Problem solved

Functional benefit

Products and services

• STC-15 First-in-class oral small-molecule inhibitor of METTL3, an RNA methyltransferase. STC-15 reprograms malignant progenitor cells by modulating mRNA methylation and is the first RNA-modifying enzyme inhibitor to enter human clinical trials, currently in Phase 2 development for select sarcomas and Phase 1b/2 combination studies with checkpoint inhibitors.
• METTL1 Inhibitor Program First-in-class small-molecule inhibitors of METTL1, a tRNA methyltransferase, for the treatment of cancer. Preclinical data demonstrates pharmacological inhibition reduces tumor growth and decreases tRNA methylation and stability of tRNAs at low nanomolar concentrations with high selectivity over other RNA and protein methyltransferases.
• ADAR1 Inhibitor Program Discovery program targeting ADAR1, an RNA-modifying enzyme involved in double-stranded RNA editing. Licensed exclusively to Exelixis for global development, manufacturing, and commercialization. ADAR1 inhibition may activate innate immune response in tumor cells and sensitize tumors to immune checkpoint inhibition, with potential applicability to up to 30% of tumors in The Cancer Genome Atlas.
• RNA Modifying Enzymes Drug Discovery Platform Proprietary drug discovery platform targeting RNA modifying enzymes for the development of novel cancer therapies. The platform enables identification of first-in-class small molecule inhibitors targeting RNA methyltransferases and other RNA-modifying enzymes including METTL3, METTL1, and ADAR1, and combines mass spectrometry-based high-throughput screening with the NASE computational algorithm.

Quantifiable outcome

• 54% disease control rate at 12 weeks in sarcoma patients with one confirmed partial response
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• AlidaBiocoreTechnology or Integration · 8 January 2026Strategic collaboration using AlidaBio's EpiPlex and EpiScout NGS platforms to analyze m6A RNA modifications in clinical samples from patients treated with STC-15. Collaboration aims to identify biomarkers for patient selection by correlating m6A modification changes with clinical response.
• Coherus BioSciencescoreStrategic or Co-development Partner · 27 May 2025Clinical collaboration evaluating STC-15 in combination with LOQTORZI (toripalimab-tpzi), Coherus's next-generation PD-1 inhibitor. Phase 1b/2 study in NSCLC, HNSCC, melanoma, and endometrial cancer with up to 188 patients. Coherus supplies drug; STORM sponsors trial. Each retains commercial rights to respective compounds.
• ExelixiscoreStrategic or Co-development Partner · 14 October 2021Exclusive collaboration and license agreement for discovery and development of ADAR1 inhibitors and one additional undisclosed target. Exelixis paid $17M upfront, provides funding for discovery research, and is solely responsible for global development, manufacturing and commercialization. STORM eligible for development, regulatory and commercialization milestones plus tiered royalties on net sales.
• University of Cambridge (Gurdon Institute and Milner Therapeutics Institute)coreStrategic or Co-development Partner · 26 April 2021Long-standing research partnership with founding scientists Professor Tony Kouzarides and Professor Eric Miska. Collaboration with Gurdon Institute, Milner Therapeutics Institute, and Wellcome Sanger Institute on METTL3 research and drug discovery.
• Wellcome Sanger InstituteminorStrategic or Co-development Partner · 26 April 2021Research collaboration on METTL3 inhibitor program, supported by grants from Cancer Research UK.
• University of CambridgeminorStrategic or Co-development Partner · 3 September 2018Knowledge Transfer Partnership (KTP) grant of up to £240,000 to develop analysis platform using InterMine data warehouse software for cancer research.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Hiberion (formerly Storm exited): Early-stage precision medicine company developing small molecules targeting RNA-modifying enzymes for cancer. Closely overlaps with Storm's target class and therapeutic approach but at an earlier preclinical stage.

Direct peers

• Constellation Pharmaceuticals: Developed epigenetic cancer therapies (EZH2 inhibitors) and was acquired by MorphoSys for ~$1.7B in 2021. Most relevant precedent for a clinical-stage epigenetic-modifier biotech exiting via strategic acquisition.
• Mirati Therapeutics: Clinical-stage targeted oncology company acquired by Bristol-Myers Squibb for $4.8B in 2024. Provides a relevant exit-multiple benchmark for late-stage targeted oncology biotechs with similar clinical-development profiles.
• Foghorn Therapeutics: Clinical-stage biotech developing medicines targeting the chromatin regulatory system in oncology. Operates in the same broader epigenetic drug-discovery space with comparable target-class focus and clinical-development approach.
• Epizyme: Developed TAZVERIK (tazemetostat), an EZH2 inhibitor for epithelioid sarcoma and follicular lymphoma. Closely comparable in mechanism (epigenetic modifier in oncology), sarcoma indication overlap, and clinical/regulatory pathway.
• Kronos Bio: Clinical-stage oncology company focused on targeting dysregulated transcription and chromatin signaling pathways. Comparable in stage, target-class (epigenetic/transcriptional), and clinical development strategy against transcription factor dependencies in cancer.
• Accent Therapeutics: Direct competitor developing small-molecule inhibitors of RNA-modifying enzymes (METTL3 and other targets) for cancer. Both Accent and Storm are the leading clinical-stage biotechs targeting RNA epigenetics with similar platforms and indications.

Broad incumbents

• Blueprint Medicines: Commercial-stage targeted oncology company with kinase inhibitors (avapritinib, pralsetinib). Comparable in applying structure-based drug discovery to validated oncogenic targets, providing a useful precedent for the licensing-and-partnership model Storm pursues.

Others

• Evotec: European drug-discovery platform company, partnered with Storm since 2017 on RNA-modifying enzyme drug discovery. Comparable as a CRO/platform peer with overlapping target class and adjacent drug-discovery services model.
• Exelixis: Commercial-stage oncology company that licensed Storm's ADAR1 program in 2021 ($17M upfront plus milestones). Functions as a strategic partner and acquirer-class peer representing the kind of large biotech licensing deals Storm is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/storm_tx
• LinkedInlinkedin.com/company/storm-therapeutics-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds8 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Storm Therapeutics